Image:
Ailsa Craig of the International Biotechnology Trust
The US Presidential elections have always represented a potentially pivotal moment for the global healthcare sector because of implications on drug pricing – and the recent elections have been no different.
Some investors are understandably concerned that the power to make legislative changes granted by the Democrats' clean sweep − gaining the Presidency, House of Representatives, and the Senate − could have...
To continue reading this article...
Join Investment week
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
